We’re proud to announce Chloe Langridge as a 2025 HDBuzz Prize winner! A protein called SGTA shows promise as a target in HD therapeutics. Researchers find that increasing levels of SGTA in the cell ...

In an update from uniQure, they report that their experimental gene therapy, AMT-130, has the potential to slow Huntington’s ...

We’re proud to announce Mustafa Mehkary as a 2025 HDBuzz Prize winner! New findings reveal that the huntingtin protein is a ...

September was a landmark month in Huntington’s disease research: a gene therapy shows signs of slowing progression, plus new biomarkers, mechanistic insights and mental health advances. The field has ...

SKY-0515, an oral drug, safely lowers huntingtin in people with HD and may also reduce PMS1. This could offer a possible two-pronged approach to treat HD. SKY-0515 is now being tested in a larger ...

HDBuzz: 2024 was a big year for HD research, particularly in the clinical space. Which breakthroughs or advances in HD research from the past year are you particularly excited about? HDBuzz Editors-in ...

On 25th June 2024, Wave Life Sciences shared the results of their SELECT-HD clinical trial. This trial tested a therapy called WVE-003, designed to only lower the expanded, harmful form of the ...

While HD primarily affects the brain, people with HD have subtle changes to their nervous system that can also affect heart rate and blood pressure. The scientists who worked on this paper had ...

HDBuzz strives to be an honest and neutral source of information that Huntington’s disease (HD) families can turn to for trusted, unbiased reporting on research and clinical trial news. We’re honored ...

A new study led by researchers from University College London has helped uncover some of the earliest changes that happen in people with the gene for Huntington’s disease (HD), long before obvious ...

CRISPR is short for “clustered regularly interspaced short palindromic repeats” – quite a mouthful! That’s essentially just science-speak for short strings of DNA letters that break up repeating parts ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committee (iDMC) that ...